Your One-Stop Partner for Global Pharmaceutical R&D and Manufacturing

Founded in April 2010 and headquartered in Hong Kong, a hub of international trade, LIDE PHARMACEUTICALS LTD focuses on Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, R&D chemicals and building blocks. Serving chemical and pharmaceutical companies and research institutions worldwide, we are a one-stop provider of specialized CRO, CMO and CDMO solutions, covering process development, pilot scale-up and commercial production of key intermediates and APIs for both innovative and generic drugs, as well as technical services in molecular block design and synthesis and international regulatory document registration, empowering clients to run their global pharmaceutical business efficiently.

Since 2017, LIDE has operated a leading R&D technology platform in Wujiang, Suzhou, and established a customized R&D (CRO) center with supporting analytical testing capabilities in 2019. Serving as a frontier for lead compound screening and project evaluation, the center closes the loop across the upstream industry chain. We hold core technical strengths in asymmetric chiral synthesis, bromination, metal catalysis, nitration and hydrogenation, and deliver outstanding products and services through strong product development and commercialization capabilities.

In 2018, we built four production and synthesis workshops in the chemical industrial park of Beigou Town, Penglai, Shandong, equipped with specialized facilities for ultra-low temperature, high pressure, ultra-high temperature and high vacuum processes. In March 2021, we launched a modern manufacturing base in the Shaowu Provincial Chemical Industrial Park, Fujian, comprising GMP workshops and multiple non-GMP workshops with reactors ranging from 50 to 5,000 liters to accommodate diverse production conditions. With well-established quality management and EHS systems and a strong delivery track record, the base provides global innovative drug companies with core services spanning small-scale trials, pilot scale-up and commercial production. Our products cover the following major therapeutic areas:

In 2023, LIDE launched its strategic transformation into peptide raw materials, specializing in the R&D and production of peptides and related derivatives. We currently offer more than 60 mature drug peptide products with an annual peptide capacity exceeding one ton, and have cumulatively delivered over 20,000 custom peptides. We provide one-stop peptide services from R&D scale (mg) through pilot scale to commercial production (kgs).

Our sales network spans Hong Kong, Suzhou and Nanjing, staffed by a highly professional and dedicated team serving customers in 110 countries and regions across five continents.

Values

We always take the realization of customer value as our highest guideline, uphold altruistic thinking and a service mindset, and remain customer-centric—responding quickly and delivering value-added services across project initiation, progress tracking, proactive feedback, sample testing, product delivery and market outlook analysis. It is our fundamental principle to deliver products that meet customers' quality standards together with the required supporting documents. Since our founding, we have maintained a strong reputation with zero complaints. Internally, we have built comprehensive compensation, promotion and performance evaluation systems to safeguard employee benefits and help them fulfill their needs and aspirations at every career stage.

Vision

We are committed to building a century-old enterprise, advancing continuously, driving new drug development and manufacturing, enabling customer success, and jointly promoting the rapid growth of the global pharmaceutical industry.